feladilimab   Click here for help

GtoPdb Ligand ID: 11649

Synonyms: GSK-3359609
Compound class: Antibody
Comment: Feladilimab (GSK3359609) is a humanized IgG4 anti-ICOS monoclonal antibody that was developed for immuno-oncology potential. It was withdrawn from development in mid-2021 following a failure to demonstrate efficacy in a Phase 2 trial in patients with non-small cell lung cancer.
Peptide sequence analysis suggests that feladilimab is derived from clone H2L5 hIgG4PE in GSK patent WO2016120789 [1]. Feladilimab competes with ICOS ligand for binding to ICOS.
Click here for help
Classification Click here for help
Compound class Antibody
Ligand families/groups Immune checkpoint modulators
International Nonproprietary Names Click here for help
INN number INN
11311 feladilimab
Synonyms Click here for help
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 1010
Other databases
GtoPdb PubChem SID 442878675
Search PubMed clinical trials feladilimab
Search PubMed titles feladilimab
Search PubMed titles/abstracts feladilimab